Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19

Saved in:

Bibliographic Details
Published in	Antimicrobial agents and chemotherapy Vol. 64; no. 6
Main Authors	Hoffmann, Markus, Schroeder, Simon, Kleine-Weber, Hannah, Müller, Marcel A., Drosten, Christian, Pöhlmann, Stefan
Format	Journal Article
Language	English
Published	United States American Society for Microbiology 21.05.2020
Subjects	Betacoronavirus Commented On Coronavirus Infections COVID-19 Editor's Pick Guanidines Letter to the Editor Letters to the Editor Pandemics Peptidyl-Dipeptidase A Pneumonia, Viral Protease Inhibitors SARS Virus SARS-CoV-2 Virus Internalization COVID-19 TMPRSS2 coronavirus SARS-CoV-2
Online Access	Get full text
ISSN	0066-4804 1098-6596 1098-6596
DOI	10.1128/AAC.00754-20

More Information
Bibliography:	SourceType-Scholarly Journals-1 ObjectType-Correspondence-1 ObjectType-Commentary-2 content type line 23 Citation Hoffmann M, Schroeder S, Kleine-Weber H, Müller MA, Drosten C, Pöhlmann S. 2020. Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob Agents Chemother 64:e00754-20. https://doi.org/10.1128/AAC.00754-20.
ISSN:	0066-4804 1098-6596 1098-6596
DOI:	10.1128/AAC.00754-20